CASI Pharmaceuticals (CASIF) Current Assets (2021 - 2025)

CASI Pharmaceuticals has reported Current Assets for 5 years, with the latest figure at $13.5 million in Q4 2025.

• For the quarter ending Q4 2025, Current Assets fell 66.0% year-over-year to $13.5 million; the trailing twelve-month figure through Dec 2025 stood at $13.5 million (down 66.0% YoY), and the FY2025 full-year result was $13.5 million, down 66.0% from the prior year.
• Current Assets for Q4 2025 stood at $13.5 million, up from $11.9 million in the prior quarter.
• The five-year high for Current Assets was $61.0 billion in Q2 2023, with the low at $11.9 million in Q3 2025.
• Historically, Current Assets has averaged $16.8 billion across 5 years, with a median of $62.0 million in 2021.
• Annual changes were most pronounced in 2023 — Current Assets jumped 80724.81% — and 2025, when it plunged 99.95%.
• CASI Pharmaceuticals' Current Assets stood at $62.0 million in 2021, then increased by 18.48% to $73.4 million in 2022, then jumped by 80724.81% to $59.3 billion in 2023, then sank by 99.93% to $39.6 million in 2024, then tumbled by 66.0% to $13.5 million in 2025.
• The last three Current Assets figures came in at $13.5 million (Q4 2025), $11.9 million (Q3 2025), and $18.2 million (Q2 2025), per Business Quant data.